Funktionelle Insulintherapie / Functional Insulin Treatment

Über Uns / About us

Forschung / Research

Lehre / Graduate Teaching

FIT SEMINAR for HCP 2009

Bücher&EDV / Books&Media

Schulung/ Education

Patienteninfo&Ordination

Kontakt / Contact Us

Erlebnisse / Testimonials

Links

Functional Insulin Treatment: Competent Patient Leadership

Willkommen bei

Competent Patient Leadership

Welcome!


ISO 9001 certified

Competent Patient Leadership


 

Research Group

Functional Rehabilitation and Group Education, Vienna


We are the ISO-9001 certified research group, headed by Professor Kinga Howorka, MD; non-profit organisation providing medical research, structured individual and group education for self-treatment in diabetes and related diseases. Our main focus is diabetes mellitus with special interest in Type 1 diabetes, pregnancy in diabetes and/or hypoglycemia unawareness. Further on, components of metabolic syndrome such as hypertension, dyslipidemia and obesity are of particular interest, as well.


Physically we work at present in Vienna, Austria
and we closely cooperate with Medical University of Vienna, Center of Biomedical Engineering and Physics and Center of Public Health, as well as with other medical university research and/or pharmaceuticals research groups.


Functional Insulin Treatment means that insulin is used functionally to imitate insulin production in a healthy pancreas. It is used functionally by separate replacement of:

  • Basal - insulin necessary to sustain the body while fasting, and

  • Prandial - or meal-related insulin, and

  • Correction insulin, necessary to lower blood glucose levels to the preferred target.

This system allows to adjust the insulin supply you need with 4 to 6 daily insulin injections or with an insulin pump. The insulin is personalized to individual requirements based on several daily blood glucose self-measurements, appetite (requirements for food) or fasting needs.

Two daily injections of delayed-acting insulin like NPH, Levemir® or once daily Lantus® (long-acting insulin analogs) are needed to cover basal, or fasting, insulin needs. Eating, or correcting high blood glucose levels requires a rapid-acting insulin such as Regular or Humalog®, NovoRapid® or Apidra® (rapid insulin analogs).

Regarding risk potentially associated to Lantus®, read the official statement of the European Association for the Study of Diabetes: http://webcast.easd.org/press/glargine/glargine.htm

Pressemeldung von diabetesDE und DDG zu Lantus:
http://www.deutsche-diabetes-gesellschaft.de/redaktion/news/Lantus.php

Hier finden Sie die Stellungnahme der Österreichischen Diabetes Gesellschaft (Prof.Dr. Bernhard Ludvik)

Insulin glargine and malignancy: an unwarranted alarm


No evidence of increased risk of malignancies in patients

with diabetes treated with insulin detemir: a meta-analysis


Combined randomised controlled trial experience

of malignancies in studies using insulin glargine



(c) 2005-2009 by Kinga Howorka, Jiri Pumprla.
Research Group Functional Rehabilitation and Group Education eV.,
Center of Biomedical Engineering & Physics, Medical University Vienna, Austria